155 related articles for article (PubMed ID: 28673362)
1. Clinical outcomes of retrograde intra-arterial chemotherapy concurrent with radiotherapy for elderly oral squamous cell carcinoma patients aged over 80 years old.
Hayashi Y; Mitsudo K; Sakuma K; Iida M; Iwai T; Nakashima H; Okamoto Y; Koizumi T; Oguri S; Hirota M; Kioi M; Koike I; Hata M; Tohnai I
Radiat Oncol; 2017 Jul; 12(1):112. PubMed ID: 28673362
[TBL] [Abstract][Full Text] [Related]
2. Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for stage III and IV oral cancer: analysis of therapeutic results in 112 cases.
Mitsudo K; Koizumi T; Iida M; Iwai T; Nakashima H; Oguri S; Kioi M; Hirota M; Koike I; Hata M; Tohnai I
Radiother Oncol; 2014 May; 111(2):306-10. PubMed ID: 24746571
[TBL] [Abstract][Full Text] [Related]
3. Treatment results of alternating chemoradiotherapy followed by proton beam therapy boost combined with intra-arterial infusion chemotherapy for stage III-IVB tongue cancer.
Takayama K; Nakamura T; Takada A; Makita C; Suzuki M; Azami Y; Kato T; Hayashi Y; Ono T; Toyomasu Y; Hareyama M; Kikuchi Y; Daimon T; Mitsudo K; Tohnai I; Fuwa N
J Cancer Res Clin Oncol; 2016 Mar; 142(3):659-67. PubMed ID: 26521257
[TBL] [Abstract][Full Text] [Related]
4. Chemoradiotherapy using retrograde superselective intra-arterial infusion for tongue cancer: Analysis of therapeutic results in 118 cases.
Mitsudo K; Hayashi Y; Minamiyama S; Ohashi N; Iida M; Iwai T; Oguri S; Koizumi T; Kioi M; Hirota M; Koike I; Hata M; Tohnai I
Oral Oncol; 2018 Apr; 79():71-77. PubMed ID: 29598953
[TBL] [Abstract][Full Text] [Related]
5. Organ preservation with daily concurrent chemoradiotherapy using superselective intra-arterial infusion via a superficial temporal artery for T3 and T4 head and neck cancer.
Mitsudo K; Shigetomi T; Fujimoto Y; Nishiguchi H; Yamamoto N; Furue H; Ueda M; Itoh Y; Fuwa N; Tohnai I
Int J Radiat Oncol Biol Phys; 2011 Apr; 79(5):1428-35. PubMed ID: 20605340
[TBL] [Abstract][Full Text] [Related]
6. Phase II feasibility trial of adjuvant chemoradiotherapy with 3-weekly cisplatin for Japanese patients with post-operative high-risk squamous cell carcinoma of the head and neck.
Kiyota N; Tahara M; Okano S; Kawashima M; Matsuura K; Onozawa Y; Nibu K; Hayashi R; Yoshimura K; Ohtsu A
Jpn J Clin Oncol; 2012 Oct; 42(10):927-33. PubMed ID: 22923484
[TBL] [Abstract][Full Text] [Related]
7. Thermochemoradiation therapy using superselective intra-arterial infusion via superficial temporal and occipital arteries for oral cancer with N3 cervical lymph node metastases.
Mitsudo K; Koizumi T; Iida M; Iwai T; Oguri S; Yamamoto N; Itoh Y; Kioi M; Hirota M; Tohnai I
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e639-45. PubMed ID: 22543212
[TBL] [Abstract][Full Text] [Related]
8. Retrograde intra-arterial chemotherapy and daily concurrent proton beam therapy for recurrent oral cavity squamous cell carcinoma: Analysis of therapeutic results in 46 cases.
Hayashi Y; Nakamura T; Mitsudo K; Yamaguchi H; Ono T; Azami Y; Takayama K; Suzuki M; Hatayama Y; Tsukiyama I; Hareyama M; Kikuchi Y; Fuwa N; Tohnai I
Head Neck; 2016 Aug; 38(8):1145-51. PubMed ID: 27018982
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors and treatment outcomes of advanced maxillary gingival squamous cell carcinoma treated by intra-arterial infusion chemotherapy concurrent with radiotherapy.
Hayashi Y; Osawa K; Nakakaji R; Minamiyama S; Ohashi N; Ohya T; Iida M; Iwai T; Ozawa T; Oguri S; Koizumi T; Hirota M; Kioi M; Hata M; Mitsudo K
Head Neck; 2019 Jun; 41(6):1777-1784. PubMed ID: 30694002
[TBL] [Abstract][Full Text] [Related]
10. Retrograde superselective intra-arterial chemotherapy and daily concurrent radiotherapy for T2-4N0 tongue cancer: control of occult neck metastasis.
Minamiyama S; Mitsudo K; Hayashi Y; Iida M; Iwai T; Nakashima H; Oguri S; Ozawa T; Koizumi T; Hirota M; Kioi M; Tohnai I
Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Jul; 124(1):16-23. PubMed ID: 28434836
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
[TBL] [Abstract][Full Text] [Related]
12. Concurrent cetuximab and radiotherapy after docetaxel-cisplatin induction chemotherapy in stage III NSCLC: satellite--a phase II study from the Swedish Lung Cancer Study Group.
Hallqvist A; Wagenius G; Rylander H; Brodin O; Holmberg E; Lödén B; Ewers SB; Bergström S; Wichardt-Johansson G; Nilsson K; Ekberg L; Sederholm C; Nyman J
Lung Cancer; 2011 Feb; 71(2):166-72. PubMed ID: 20541833
[TBL] [Abstract][Full Text] [Related]
13. Daily Cisplatin and Weekly Docetaxel versus Weekly Cisplatin Intra-Arterial Chemoradiotherapy for Late T2-3 Tongue Cancer: A Pilot and Feasibility Trial.
Hayashi Y; Minamiyama S; Ohya T; Iida M; Iwai T; Koizumi T; Oguri S; Hirota M; Kioi M; Hata M; Taguri M; Mitsudo K
Medicina (Kaunas); 2018 Jul; 54(4):. PubMed ID: 30344283
[No Abstract] [Full Text] [Related]
14. Radiotherapy potentiation with weekly cisplatin compared to standard every 3 weeks cisplatin chemotherapy for locoregionally advanced head and neck squamous cell carcinoma.
Fayette J; Molin Y; Lavergne E; Montbarbon X; Racadot S; Poupart M; Ramade A; Zrounba P; Ceruse P; Pommier P
Drug Des Devel Ther; 2015; 9():6203-10. PubMed ID: 26648696
[TBL] [Abstract][Full Text] [Related]
15. Multimodality treatment including postoperative radiation and concurrent chemotherapy with weekly docetaxel is feasible and effective in patients with oral and oropharyngeal cancer.
Kovács AF; Mose S; Böttcher HD; Bitter K
Strahlenther Onkol; 2005 Jan; 181(1):26-34. PubMed ID: 15660190
[TBL] [Abstract][Full Text] [Related]
16. Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma.
Hosni A; Huang SH; Xu W; Su J; Bayley A; Bratman SV; Cho J; Giuliani M; Kim J; Ringash J; Waldron J; Spreafico A; De Almeidad J; O'Sullivan B; Goldstein D; Hope A
JAMA Otolaryngol Head Neck Surg; 2017 Apr; 143(4):368-375. PubMed ID: 28033442
[TBL] [Abstract][Full Text] [Related]
17. T-status and an oral fluoropyrimidine, S-1, adjuvant chemotherapy are prognostic factors in reduced-RADPLAT for resectable hypopharyngeal cancer.
Wakisaka N; Hirai N; Kondo S; Aga M; Nakanishi Y; Tsuji A; Endo K; Murono S; Yoshizaki T
Acta Otolaryngol; 2016 Aug; 136(8):834-40. PubMed ID: 27007816
[TBL] [Abstract][Full Text] [Related]
18. Combined modality treatment of oral and oropharyngeal cancer including neoadjuvant intraarterial cisplatin and radical surgery followed by concurrent radiation and chemotherapy with weekly docetaxel - three year results of a pilot study.
Kovács AF; Schiemann M; Turowski B
J Craniomaxillofac Surg; 2002 Apr; 30(2):112-20. PubMed ID: 12069515
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of paclitaxel plus cisplatin with concurrent radiotherapy for loco-regional esophageal squamous cell carcinoma.
Zhu HT; Ai DS; Tang HR; Badakhshi H; Fan JH; Deng JY; Zhang JH; Chen Y; Zhang Z; Xia Y; Guo XM; Jiang GL; Zhao KL
World J Gastroenterol; 2017 Jan; 23(3):540-546. PubMed ID: 28210091
[TBL] [Abstract][Full Text] [Related]
20. Disease control, survival, and functional outcome after multimodal treatment for advanced-stage tongue base cancer.
Malone JP; Stephens JA; Grecula JC; Rhoades CA; Ghaheri BA; Schuller DE
Head Neck; 2004 Jul; 26(7):561-72. PubMed ID: 15229898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
